Razvan Nutiu, Center for Proteomic Chemistry

Chemical Biology & Therapeutics

Cambridge, Massachusetts, United States

Aberrant gene expression can lead to human disease. Our research group aims to understand how disease-relevant genes are post-transcriptionally regulated and to develop novel therapies to drug the undruggable at RNA biology level. For instance, we are interested in influencing splicing choices, mRNA translation efficiency or changing the affinity of RNA-protein interactions that drive certain post-transcriptional regulation steps. Our approach is highly integrated and iterative, spanning a variety of chemical biology technologies such as high throughput screening, biochemical and cell-based functional assays, high throughput transcriptomics and next generation sequencing, structural and biophysical approaches, chemistry and computational biology. We collaborate extensively with other groups at Novartis and academic institutions, and together we build relevant tools and knowledge to treat human disease.

Selected Publications

Functional atlas of primary miRNA maturation by the Microprocessor.
Rice GM, Shivashankar V, Ma EJ, Baryza JL, Nutiu R
Mol Cell. 2020 Nov 4:S1097-2765(20)30735-8.

Pervasive Regulatory Functions of mRNA Structure Revealed by High-Resolution SHAPE Probing.
Mustoe AM, Busan S, Rice GM, Hajdin CE, Peterson BK, Ruda VM, Kubica N, Nutiu R, Baryza JL,Weeks KM.
Cell. 2018 Mar 22;173(1):181-195.

Direct measurement of DNA affinity landscapes on a high-throughput sequencing instrument.
Nutiu R, Friedman RC, Luo S, Khrebtukova I, Silva D, Li R, Zhang L, Schroth GP, Burge CB.
Nat Biotechnol. 2011 Jun 26;29(7):659-64.

Click here for additional publications.